JP2012504959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504959A5 JP2012504959A5 JP2011531018A JP2011531018A JP2012504959A5 JP 2012504959 A5 JP2012504959 A5 JP 2012504959A5 JP 2011531018 A JP2011531018 A JP 2011531018A JP 2011531018 A JP2011531018 A JP 2011531018A JP 2012504959 A5 JP2012504959 A5 JP 2012504959A5
- Authority
- JP
- Japan
- Prior art keywords
- transcription factor
- vector
- function
- polynucleotide encoding
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 claims 45
- 102000004169 proteins and genes Human genes 0.000 claims 30
- 108091023040 Transcription factor Proteins 0.000 claims 21
- 102000040945 Transcription factor Human genes 0.000 claims 21
- 102000040430 polynucleotide Human genes 0.000 claims 19
- 108091033319 polynucleotide Proteins 0.000 claims 19
- 239000002157 polynucleotide Substances 0.000 claims 19
- 210000002865 immune cell Anatomy 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000003446 ligand Substances 0.000 claims 8
- 230000001419 dependent effect Effects 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 6
- 108010057988 ecdysone receptor Proteins 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 4
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 4
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims 4
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 4
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 4
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 4
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 claims 4
- 102100035304 Lymphotactin Human genes 0.000 claims 4
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- -1 IFN-α1 Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 2
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 2
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims 2
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102100025221 CD70 antigen Human genes 0.000 claims 2
- 108010083702 Chemokine CCL21 Proteins 0.000 claims 2
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 2
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 2
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims 2
- 108700010013 HMGB1 Proteins 0.000 claims 2
- 101150021904 HMGB1 gene Proteins 0.000 claims 2
- 102100037907 High mobility group protein B1 Human genes 0.000 claims 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 2
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 2
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 2
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 claims 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 2
- 102100034980 ICOS ligand Human genes 0.000 claims 2
- 102100026720 Interferon beta Human genes 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108090000467 Interferon-beta Proteins 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102000000589 Interleukin-1 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 108010065637 Interleukin-23 Proteins 0.000 claims 2
- 108010066979 Interleukin-27 Proteins 0.000 claims 2
- 108010002386 Interleukin-3 Proteins 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 108010002616 Interleukin-5 Proteins 0.000 claims 2
- 108010002586 Interleukin-7 Proteins 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 108010002335 Interleukin-9 Proteins 0.000 claims 2
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims 2
- 108010042215 OX40 Ligand Proteins 0.000 claims 2
- 108091030071 RNAI Proteins 0.000 claims 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 108040006870 interleukin-10 receptor activity proteins Proteins 0.000 claims 2
- 108010074108 interleukin-21 Proteins 0.000 claims 2
- 102000003898 interleukin-24 Human genes 0.000 claims 2
- 108090000237 interleukin-24 Proteins 0.000 claims 2
- 108010019677 lymphotactin Proteins 0.000 claims 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 2
- 102100030703 Interleukin-22 Human genes 0.000 claims 1
- 102000013264 Interleukin-23 Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102100031789 Myeloid-derived growth factor Human genes 0.000 claims 1
- 102100033125 Transcription factor 24 Human genes 0.000 claims 1
- 101710119682 Transcription factor 24 Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10381008P | 2008-10-08 | 2008-10-08 | |
| US61/103,810 | 2008-10-08 | ||
| PCT/US2009/005510 WO2010042189A2 (en) | 2008-10-08 | 2009-10-08 | Engineered cells expressing multiple immunomodulators and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015157352A Division JP2016025858A (ja) | 2008-10-08 | 2015-08-07 | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012504959A JP2012504959A (ja) | 2012-03-01 |
| JP2012504959A5 true JP2012504959A5 (enExample) | 2012-11-29 |
Family
ID=42101134
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531018A Withdrawn JP2012504959A (ja) | 2008-10-08 | 2009-10-08 | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
| JP2015157352A Withdrawn JP2016025858A (ja) | 2008-10-08 | 2015-08-07 | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
| JP2018166324A Withdrawn JP2019000118A (ja) | 2008-10-08 | 2018-09-05 | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015157352A Withdrawn JP2016025858A (ja) | 2008-10-08 | 2015-08-07 | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
| JP2018166324A Withdrawn JP2019000118A (ja) | 2008-10-08 | 2018-09-05 | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9492482B2 (enExample) |
| EP (1) | EP2356219A4 (enExample) |
| JP (3) | JP2012504959A (enExample) |
| KR (2) | KR101629071B1 (enExample) |
| CN (1) | CN102575227A (enExample) |
| AU (3) | AU2009302804B2 (enExample) |
| BR (1) | BRPI0920679A2 (enExample) |
| CA (1) | CA2739902A1 (enExample) |
| IL (3) | IL212184A (enExample) |
| MX (1) | MX340972B (enExample) |
| RU (1) | RU2573912C2 (enExample) |
| WO (1) | WO2010042189A2 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010540534A (ja) | 2007-09-28 | 2010-12-24 | イントレキソン コーポレーション | 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用 |
| KR20180108886A (ko) * | 2010-03-23 | 2018-10-04 | 인트렉손 코포레이션 | 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도 |
| US9402919B2 (en) * | 2011-03-04 | 2016-08-02 | Intrexon Corporation | Vectors conditionally expressing protein |
| KR102256613B1 (ko) * | 2011-09-08 | 2021-05-27 | 프레시전 인코포레이티드 | 결정성 디아실하이드라진 및 이의 용도 |
| WO2013040371A2 (en) * | 2011-09-16 | 2013-03-21 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
| EP2766035B1 (en) * | 2011-10-11 | 2018-03-28 | Universität Zürich Prorektorat MNW | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
| CN102631671B (zh) * | 2012-04-05 | 2014-11-26 | 倪国颖 | 提高疫苗诱导的细胞毒性t细胞反应的治疗性疫苗 |
| WO2014169255A1 (en) * | 2013-04-11 | 2014-10-16 | The Brigham And Women's Hospital, Inc. | Methods and compositions of treating autoimmune diseases |
| ES2708749T3 (es) * | 2013-04-18 | 2019-04-11 | Tilt Biotherapeutics Oy | Terapia celular adoptiva mejorada |
| US12421502B2 (en) | 2013-04-18 | 2025-09-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| AU2014352749A1 (en) * | 2013-11-22 | 2016-06-09 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| ES2927366T3 (es) * | 2014-10-09 | 2022-11-04 | Univ Yamaguchi | Vector de expresión de CAR y células T que expresan CAR |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| JP6755465B2 (ja) * | 2014-12-03 | 2020-09-16 | 株式会社アネロファーマ・サイエンス | 共発現プラスミド |
| WO2016094481A1 (en) | 2014-12-09 | 2016-06-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
| EP3770252A1 (en) * | 2015-01-26 | 2021-01-27 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
| EP3804741A3 (en) * | 2015-02-24 | 2021-07-14 | Board of Regents, The University of Texas System | Selection methods for genetically-modified t cells |
| TWI739740B (zh) * | 2015-04-22 | 2021-09-21 | 德商奎爾法克股份有限公司 | 用於治療腫瘤疾病之含有ｒｎａ的組成物 |
| US20170020922A1 (en) * | 2015-07-16 | 2017-01-26 | Batu Biologics Inc. | Gene editing for immunological destruction of neoplasia |
| EP3347373A1 (en) | 2015-10-10 | 2018-07-18 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| CA3004742A1 (en) | 2015-11-11 | 2017-05-18 | Intrexon Corporation | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
| EP3390643B8 (en) * | 2015-12-18 | 2023-08-02 | OncoSec Medical Incorporated | Plasmid constructs for heterologous protein expression and methods of use |
| MX2018008413A (es) | 2016-01-08 | 2019-02-20 | Replimune Ltd | Virus oncolitico modificado. |
| MY190565A (en) * | 2016-03-17 | 2022-04-27 | Univ Yamaguchi | Immunocompetent cell and expression vector expressing regulatory factors of immune function |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2017214333A1 (en) | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| TWI847958B (zh) * | 2016-07-05 | 2024-07-11 | 英屬開曼群島商北極星藥業集團股份有限公司 | 用精胺酸耗盡劑進行之組合癌症免疫療法 |
| UY37343A (es) | 2016-07-25 | 2018-02-28 | Intrexon Corp | Control del fenotipo en plantas |
| JP2018023343A (ja) * | 2016-08-12 | 2018-02-15 | 国立大学法人山口大学 | 細胞培養用培地、及び細胞培養方法 |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| WO2018132494A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| JP6874147B2 (ja) * | 2017-02-28 | 2021-05-19 | ジーンメディスン・カンパニー・リミテッド | 腫瘍特異的殺傷アデノウイルスおよび免疫チェックポイント阻害剤を含む抗癌用組成物 |
| EP4317422A3 (en) | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| CA3060443A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| IL270990B2 (en) | 2017-06-07 | 2024-02-01 | Precigen Inc | Expression of new cell markers |
| US20200123566A1 (en) * | 2017-06-13 | 2020-04-23 | Oncosec Medical Incorporated | Multigene construct for immune-modulatory protein expression and methods of use |
| SG11202005036RA (en) | 2018-01-25 | 2020-06-29 | I Mab Biopharma Us Ltd | Anti-pd-l1 antibody and il-7 fusions |
| WO2019151760A1 (ko) * | 2018-02-02 | 2019-08-08 | 주식회사 에스엘백시젠 | 신규 다가 hpv 백신 조성물 |
| WO2019151759A1 (ko) * | 2018-02-02 | 2019-08-08 | 주식회사 에스엘백시젠 | 신규 백신 면역보조제 |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| WO2019173465A1 (en) | 2018-03-06 | 2019-09-12 | Intrexon Corporation | Human papillomavirus vaccines and uses of the same |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| AU2019271819A1 (en) | 2018-05-15 | 2021-01-14 | Crage Medical Co., Limited | Genetically engineered cell and application thereof |
| AU2019286345A1 (en) * | 2018-06-13 | 2021-01-07 | The Council Of The Queensland Institute Of Medical Research | Viral detection assay |
| US20210395773A1 (en) * | 2018-06-27 | 2021-12-23 | Precigen, Inc. | In vivo controlled combination therapy for treatment of cancer |
| WO2020014235A1 (en) * | 2018-07-09 | 2020-01-16 | The Regents Of The University Of California | Gene targets for t-cell-based immunotherapy |
| CN113164518B (zh) | 2018-10-17 | 2025-06-24 | 森迪生物科学公司 | 组合癌症免疫疗法 |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| TWI850282B (zh) * | 2018-11-27 | 2024-08-01 | 香港商弘年發展有限公司 | 用於治療癌症之質體建構體和使用方法 |
| JP2022513639A (ja) * | 2018-11-29 | 2022-02-09 | ヴァイロジン バイオテック カナダ リミテッド | 低神経毒性ｈｓｖベクター |
| WO2020131656A1 (en) * | 2018-12-17 | 2020-06-25 | Immune Design Corp. | Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer |
| WO2020206056A1 (en) | 2019-04-04 | 2020-10-08 | Greenvenus Llc | Peptides and methods of plant protection |
| CN110354260B (zh) * | 2019-08-19 | 2020-06-26 | 启辰生生物科技(珠海)有限公司 | 免疫增强剂、药物组合物及其应用 |
| CN110732021B (zh) * | 2019-11-21 | 2020-08-25 | 北京启辰生生物科技有限公司 | 用于解除肿瘤免疫抑制的组合物及其应用 |
| WO2021102287A1 (en) * | 2019-11-22 | 2021-05-27 | Ziopharm Oncology, Inc. | Methods of treating glioblastoma |
| CN110904050B (zh) * | 2019-12-16 | 2021-02-05 | 启辰生生物科技(珠海)有限公司 | 工程化抗原递呈细胞、免疫调节组合物及应用 |
| CN113005090A (zh) * | 2019-12-20 | 2021-06-22 | 上海细胞治疗集团有限公司 | 共表达趋化因子和共刺激分子的dc细胞及其应用 |
| JP7543419B2 (ja) * | 2020-02-18 | 2024-09-02 | ヴァクディアグン バイオテクノロジー カンパニー リミテッド | 組換えウイルスベクター、それを含む免疫組成物及び用途 |
| MX2022011423A (es) * | 2020-03-16 | 2022-11-09 | Univ Brussel Vrije | Una mezcla de arnm para mejorar la potencia de células dendríticas. |
| CN112029730A (zh) * | 2020-05-20 | 2020-12-04 | 深圳市芥至和生物科技有限公司 | 一种基因修饰的间充质干细胞及其应用 |
| US20230203442A1 (en) * | 2020-06-09 | 2023-06-29 | Samsung Life Public Welfare Foundation | Genetically-modified cell line for nk cell activation and amplification, and use thereof |
| WO2022081776A1 (en) | 2020-10-13 | 2022-04-21 | Kriya Therapeutics, Inc. | Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer |
| CN116426483B (zh) * | 2021-12-30 | 2024-02-23 | 南京紫珑生物科技有限公司 | Cd258蛋白在免疫治疗中的应用 |
| CN114426585B (zh) * | 2022-02-15 | 2023-10-03 | 广东香雪干细胞再生医学科技有限公司 | 融合蛋白及其表达细胞株与应用 |
| CN115433734B (zh) * | 2022-06-01 | 2025-03-04 | 北京奇糖科技有限公司 | 核酸片段及其在制备肿瘤疫苗中的应用 |
| CN119470910A (zh) * | 2024-11-01 | 2025-02-18 | 安徽医科大学 | 一种IL-12p70蛋白在认知障碍疾病中的应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| EP0680517B2 (en) | 1993-01-21 | 2005-01-19 | President And Fellows Of Harvard College | Methods and diagnostic kits utilizing mammalian stress promoters to determine toxicity of a compound |
| US5698413A (en) | 1993-05-05 | 1997-12-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of evaluating chemotherapeutic agents in vivo |
| US20040265288A1 (en) | 1995-03-08 | 2004-12-30 | Gilman Michael Z. | New applications of gene therapy technology |
| US5744304A (en) | 1995-05-30 | 1998-04-28 | Board Of Regents, The University Of Texas System | Inflammation-induced expression of a recombinant gene |
| US6306649B1 (en) | 1995-06-27 | 2001-10-23 | Ariad Gene Therapeutics, Inc. | Heterologous transcription factors |
| US5922685A (en) | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
| US20040086494A1 (en) | 1996-10-07 | 2004-05-06 | John Constance Mary | Immune privileged cells for delivery of proteins and peptides |
| AU6908998A (en) | 1996-10-29 | 1998-05-22 | Baylor College Of Medicine | Modified glucocorticoid receptors, glucocorticoid receptors/progesterone receptors hybrids |
| US20040103448A1 (en) | 1997-09-05 | 2004-05-27 | Anders Bjorklund | Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain |
| DE69815707T2 (de) | 1997-11-20 | 2004-07-01 | Vical, Inc., San Diego | Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür |
| US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| US6866842B1 (en) | 1998-05-01 | 2005-03-15 | University Of Pittsburgh | Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction |
| US7279565B2 (en) | 1998-05-05 | 2007-10-09 | Richard Voellmy | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| US6482405B1 (en) | 1998-09-15 | 2002-11-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | In situ injection of antigen-presenting cells with genetically enhanced cytokine expression |
| WO2000031286A1 (en) | 1998-11-20 | 2000-06-02 | Valentis, Inc. | Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods |
| US6365385B1 (en) | 1999-03-22 | 2002-04-02 | Duke University | Methods of culturing and encapsulating pancreatic islet cells |
| US6696272B1 (en) | 1999-06-02 | 2004-02-24 | Hsc Research & Development Limited Partnership | Products and methods for gaucher disease therapy |
| ATE338135T1 (de) | 2000-03-22 | 2006-09-15 | Rheogene Holdings Inc | Induziertes genexpressionssystem basierend auf ecdysonrezeptoren |
| DE60138404D1 (de) * | 2000-09-25 | 2009-05-28 | Baylor College Medicine | Verbessertes system zur regulation der transgenexpression |
| US20030180719A1 (en) | 2001-04-13 | 2003-09-25 | Thomas Herget | Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections |
| AU2002307393A1 (en) | 2001-04-20 | 2002-11-05 | The Salk Institute For Biological Studies | Inducible expression of transfected genes |
| US20030221203A1 (en) | 2001-10-03 | 2003-11-27 | Agha-Mohammadi Siamak | High efficiency regulatable gene expression system |
| DE60234115D1 (de) * | 2001-11-29 | 2009-12-03 | Dandrit Biotech As | Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier |
| GB0216286D0 (en) | 2002-07-15 | 2002-08-21 | Univ Leeds | Network |
| JP2006502716A (ja) | 2002-10-14 | 2006-01-26 | エフ．ホフマン−ラ ロシュ アーゲー | 移植可能な細胞 |
| WO2004073641A2 (en) * | 2003-02-18 | 2004-09-02 | Kevin Slawin | Induced activation in dendritic cells |
| US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| CA2517245C (en) | 2003-02-28 | 2009-01-20 | Mcgill University | Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
| US7456315B2 (en) * | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| CA2519680A1 (en) * | 2003-03-28 | 2004-11-18 | The Scripps Research Institute | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
| CA2535029C (en) | 2003-08-07 | 2013-07-16 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| WO2005033297A1 (en) | 2003-09-19 | 2005-04-14 | The Rockefeller University | Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells |
| US20070053845A1 (en) | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
| WO2005099773A1 (en) | 2004-04-05 | 2005-10-27 | University Of Vermont And State Agricultural College | Use of erythropoietin for treatment of cancer |
| US7704714B2 (en) | 2004-07-26 | 2010-04-27 | Agency For Science, Technology & Research | Encapsulation of cells in biologic compatible scaffolds by coacervation of charged polymers |
| US20060067942A1 (en) | 2004-09-24 | 2006-03-30 | Salama Zoser B | Pharmaceutical agent comprising amino acids, peptides, proteins and/or fractions and fragments thereof and the use of same in the prophylaxis and treatment of immune system deficiency in humans and animals |
| EP1885858A2 (en) | 2005-05-19 | 2008-02-13 | Bayer Schering Pharma Aktiengesellschaft | Treatment of disease using an improved regulated expression system |
| US7868159B2 (en) | 2005-06-23 | 2011-01-11 | Baylor College Of Medicine | Modulation of negative immune regulators and applications for immunotherapy |
| US20070036770A1 (en) | 2005-08-12 | 2007-02-15 | Wagner Darrell O | Biologic device for regulation of gene expression and method therefor |
| WO2007057436A2 (en) | 2005-11-18 | 2007-05-24 | Ares Trading S.A. | Interferon in influenza |
| WO2007078922A2 (en) | 2005-12-30 | 2007-07-12 | Neurotech Usa Inc. | Micronized device for the delivery of biologically active molecules and methods of use thereof |
| US20080181874A1 (en) | 2007-01-29 | 2008-07-31 | Alexander Kharazi | Cell composition and method for treating cancer |
| US20080241100A1 (en) | 2007-03-27 | 2008-10-02 | Stefan Strobl | Pharmaceutical composition comprising a cytokine |
| JP5881291B2 (ja) * | 2007-05-29 | 2016-03-09 | イントレキソン コーポレーション | エクジソン受容体複合体を通して外因性遺伝子の発現を調節するためのキラルジアシルヒドラジンリガンド |
| WO2009009115A2 (en) | 2007-07-11 | 2009-01-15 | Nevsky Pharmaceutical Development | Liposome compositions for treatment of hepatitis c |
| CN101835908A (zh) | 2007-08-23 | 2010-09-15 | 英特瑞克斯顿股份有限公司 | 诊断疾病的方法和组合物 |
| JP2010540534A (ja) | 2007-09-28 | 2010-12-24 | イントレキソン コーポレーション | 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用 |
| ES2636460T3 (es) * | 2007-10-08 | 2017-10-05 | Intrexon Corporation | Células dendríticas modificadas por ingeniería y usos para el tratamiento del cáncer |
| KR20180108886A (ko) | 2010-03-23 | 2018-10-04 | 인트렉손 코포레이션 | 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도 |
-
2009
- 2009-10-08 EP EP09819559.7A patent/EP2356219A4/en not_active Withdrawn
- 2009-10-08 WO PCT/US2009/005510 patent/WO2010042189A2/en not_active Ceased
- 2009-10-08 KR KR1020137025903A patent/KR101629071B1/ko not_active Expired - Fee Related
- 2009-10-08 CA CA2739902A patent/CA2739902A1/en not_active Abandoned
- 2009-10-08 KR KR1020117010348A patent/KR101361416B1/ko not_active Expired - Fee Related
- 2009-10-08 AU AU2009302804A patent/AU2009302804B2/en not_active Ceased
- 2009-10-08 MX MX2011003762A patent/MX340972B/es active IP Right Grant
- 2009-10-08 CN CN200980150164XA patent/CN102575227A/zh active Pending
- 2009-10-08 BR BRPI0920679A patent/BRPI0920679A2/pt not_active IP Right Cessation
- 2009-10-08 US US13/123,129 patent/US9492482B2/en not_active Expired - Fee Related
- 2009-10-08 JP JP2011531018A patent/JP2012504959A/ja not_active Withdrawn
- 2009-10-08 RU RU2011113660/10A patent/RU2573912C2/ru not_active IP Right Cessation
-
2011
- 2011-04-06 IL IL212184A patent/IL212184A/en active IP Right Grant
-
2015
- 2015-08-07 JP JP2015157352A patent/JP2016025858A/ja not_active Withdrawn
- 2015-09-30 AU AU2015234302A patent/AU2015234302B2/en not_active Ceased
- 2015-10-06 US US14/876,126 patent/US20160089398A1/en not_active Abandoned
- 2015-10-25 IL IL242254A patent/IL242254A0/en unknown
-
2016
- 2016-09-26 US US15/275,943 patent/US10046049B2/en not_active Expired - Fee Related
-
2017
- 2017-05-16 AU AU2017203273A patent/AU2017203273A1/en not_active Abandoned
- 2017-08-14 IL IL253985A patent/IL253985B/en active IP Right Grant
-
2018
- 2018-05-24 US US15/988,333 patent/US20180333486A1/en not_active Abandoned
- 2018-09-05 JP JP2018166324A patent/JP2019000118A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504959A5 (enExample) | ||
| JP2016025858A5 (enExample) | ||
| RU2011113660A (ru) | Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения | |
| Zhong et al. | Cytokines and chemokines in HBV infection | |
| Brempelis et al. | Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses | |
| Wang et al. | Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis | |
| JP2017525364A5 (enExample) | ||
| CA2956987C (en) | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells | |
| González et al. | Tumor cell lysates as immunogenic sources for cancer vaccine design | |
| Mitchell et al. | Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells | |
| Kaech et al. | Transcriptional control of effector and memory CD8+ T cell differentiation | |
| King et al. | A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance | |
| AU2018244221B2 (en) | ANK and IL-12 compositions and methods | |
| Kang et al. | Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects | |
| Moschella et al. | Combination strategies for enhancing the efficacy of immunotherapy in cancer patients | |
| Aivaliotis et al. | How do cytokines trigger genomic instability? | |
| JP2008515439A5 (enExample) | ||
| JP2010539993A5 (enExample) | ||
| Yang et al. | Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy | |
| Shen et al. | Tumor-associated macrophages, dendritic cells, and neutrophils: biological roles, crosstalk, and therapeutic relevance | |
| Im et al. | Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends | |
| Conforti et al. | Linear DNA amplicons as a novel cancer vaccine strategy | |
| Dravid et al. | Phenotype and fate of liver-resident CD8 T cells during acute and chronic hepacivirus infection | |
| Rajayi et al. | Cancer stem cells targeting; the lessons from the interaction of the immune system, the cancer stem cells and the tumor niche | |
| Setoguchi et al. | ThPOK derepression is required for robust CD8 T cell responses to viral infection |